



Nimenrix

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
II/0130/G	This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.f - Change in the specification parameters	21/03/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS</p> <p>B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p>				
IAIN/0134	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	28/02/2024		Annex II and PL	
IB/0132/G	<p>This was an application for a group of variations.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>	06/02/2024	n/a		
IB/0133/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>	24/01/2024	n/a		

	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
IB/0131	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	07/12/2023	n/a		
PSUSA/10044 /202304	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	30/11/2023	n/a		PRAC Recommendation - maintenance
II/0127	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	30/11/2023	n/a		
II/0129/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a	09/11/2023	n/a		

	<p>biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p>				
II/0126/G	<p>This was an application for a group of variations.</p> <p>B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier</p> <p>B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability</p>	13/07/2023	n/a		
II/0125/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a</p>	25/05/2023	n/a		

	<p>starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>				
II/0120/G	<p>This was an application for a group of variations.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a</p>	30/03/2023	n/a		

	<p>biological/immunological AS</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>				
IB/0124	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	31/01/2023	n/a		
IB/0122	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	31/01/2023	n/a		
IB/0121/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>	31/01/2023	n/a		

	<p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.c.1.z - Change in immediate packaging of the AS - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p>				
IA/0123	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	12/12/2022	n/a		
PSUSA/10044 /202204	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	01/12/2022	n/a		PRAC Recommendation - maintenance
IB/0118/G	<p>This was an application for a group of variations.</p> <p>B.II.b.4.a - Change in the batch size (including batch</p>	04/08/2022	n/a		

	<p>size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size</p> <p>B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products</p>				
IB/0117/G	<p>This was an application for a group of variations.</p> <p>B.II.z - Quality change - Finished product - Other variation</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>	09/06/2022	n/a		
IA/0116	A.7 - Administrative change - Deletion of manufacturing sites	12/05/2022	23/02/2023	Annex II and PL	

II/0115	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	31/03/2022	23/02/2023	SmPC and Annex II	
PSUSA/10044/202104	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	16/12/2021	28/02/2022		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10044/202104.
IB/0114	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	24/11/2021	n/a		
IB/0113	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	24/11/2021	n/a		
II/0112	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	18/11/2021	n/a		
II/0111/G	This was an application for a group of variations. B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is	30/09/2021	n/a		

	<p>a biological/immunological medicinal product and the change requires an assessment of comparability</p> <p>B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p>				
II/0108/G	<p>This was an application for a group of variations.</p> <p>B.II.z - Quality change - Finished product - Other variation</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p>	02/09/2021	n/a		
IB/0109/G	<p>This was an application for a group of variations.</p> <p>B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction</p> <p>B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction</p>	05/05/2021	n/a		
IA/0107/G	<p>This was an application for a group of variations.</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion</p>	09/04/2021	n/a		

	<p>of a non-significant in-process test</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p>				
PSUSA/10044/202004	<p>Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)</p>	10/12/2020	18/02/2021	SmPC and PL	<p>Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/10044/202004.</p>
II/0105	<p>To update section 5.1 Pharmacodynamic properties of the SmPC with information regarding the effectiveness of Nimenrix, to include real-world data from the Netherlands describing the impact of a single dose of Nimenrix on the prevention of meningococcal disease. In addition, a cross-reference to section 4.2 Posology and method of administration of the SmPC was included, to direct the physicians attention to the robust persistence and booster data in section 5.1 and information in section 4.4 Special warnings and precautions for use.</p> <p>In addition, the MAH took the opportunity to include minor editorial changes to the SmPC and to bring the Product information in line with the latest QRD update.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	11/02/2021	28/02/2022	SmPC and PL	<p>SmPC new text (Section 5.1) Impact of a single dose of Nimenrix.</p> <p>In 2018, the Netherlands added Nimenrix to the national immunisation programme as a single dose for toddlers at 14 months of age to replace the meningococcal C conjugate vaccine. A catch-up campaign with a single dose of Nimenrix for adolescents 14-18 years of age also initiated in 2018, and it became routine in 2020 leading to a toddler and adolescent national immunisation programme. Within two years, the incidence of meningococcal disease caused by groups C, W, and Y was significantly reduced by 100% (95% CI: 14, 100) in individuals 14-18 years of age, 85% (95% CI: 32, 97) in all vaccine eligible ages (direct effect), and 50% (95% CI: 28, 65) in non-vaccine eligible ages (indirect effect). The impact of Nimenrix was primarily driven by a reduction in group W disease.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p>

IA/0106	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	21/12/2020	n/a		
IB/0104	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	03/11/2020	18/02/2021	SmPC and PL	
IB/0103	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	09/10/2020	n/a		
II/0099/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p>	23/07/2020	18/02/2021	Annex II	

change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product

B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method

<p>method at the site is a biol/immunol method</p> <p>B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p>				
---	--	--	--	--

	<p>B.I.c.1.z - Change in immediate packaging of the AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p>				
II/0098	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	09/07/2020	n/a		
IB/0100	B.I.z - Quality change - Active substance - Other variation	29/06/2020	n/a		
IA/0101	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a	18/06/2020	n/a		

	Member State				
II/0096	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	30/01/2020	18/02/2021	SmPC and PL	
II/0095/G	<p>This was an application for a group of variations.</p> <p>Grouping of variations to support the introduction of Pfizer Ireland Pharmaceuticals (Grange Castle Business Park, Clondalkin, Dublin 22, Ireland) as an alternative manufacturing and quality control testing site for the MenAAH-TT, MenCAH-TT, MenW-TT and MenY-TT Drug Substances.</p> <p>Grouping of variations to support the registration of a new vial/vial presentation (EU/1/12/767/008) to replace the existing vial/ampoule presentations. As a consequence of the introduction of the new vial/vial presentation, the vial/ampoule presentations (EU/1/12/767/005-006-007) are being withdrawn. Hence, the 0.9% NaCl Diluent in ampoules (primary packaging container) as currently manufactured at Delpharm Belgium is withdrawn, as well as the associated secondary packaging site (CRNA Belgium) used for the related pack-size. This grouping of variations supports the introduction of Pfizer Puurs Belgium as a manufacturing and quality control site for the 0.9% NaCl Diluent in vials used for MenACWY-TT Drug Product reconstitution for the new vial/vial presentation. In addition, release specifications have been updated to align with</p>	16/01/2020	18/02/2021	SmPC, Labelling and PL	

compendial requirements.

Product Information (PI) revisions in line with the above changes affect Annex I, IIIA and IIIB, as well as Annex A (All Authorised Presentations). In addition, the MAH took the opportunity to align SmPC section 4.4 and Annex II with the latest QRD requirement.

A.7 - Administrative change - Deletion of manufacturing sites

B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products

B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place

B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation

B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products

B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging

	<p>container without a complete deletion of a strength or pharmaceutical form</p> <p>B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product</p>				
II/0094/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test</p>	16/01/2020	18/02/2021	Annex II	

method at the site is a biol/immunol method
B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method
B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method
B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS
B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method
B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation
B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure

IB/0097/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p>	17/12/2019	n/a		
PSUSA/10044 /201904	<p>Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)</p>	31/10/2019	n/a		PRAC Recommendation - maintenance
II/0092/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability</p> <p>B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products</p> <p>B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier</p>	12/09/2019	n/a		
IB/0093	<p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>	06/09/2019	n/a		
IB/0090/G	<p>This was an application for a group of variations.</p>	02/07/2019	n/a		

	<p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>				
IA/0089	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	06/05/2019	n/a		
II/0084	<p>Update of section 4.2 of the SmPC in order to update the posology information in infants, based on data from study MenACWY-TT-087 (a phase IIIb, controlled, randomised, open study aimed to demonstrate the immunogenicity and safety of Nimenrix in healthy infants) and MenACWY-TT-083 (an open-label, randomised and active controlled study).</p> <p>As a consequence, sections 4.4, 4.8 and 5.1 were updated.</p> <p>The MAH took the opportunity to include editorial changes in sections 4.4 and 4.8 of the SmPC.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	28/02/2019	04/10/2019	SmPC and PL	<p>The Nimenrix posology instructions were given for infants (i) at 6-12 weeks of age and (ii) at >1yr old, thus leaving a gap in advice for those between 12 weeks and 1 year of age.</p> <p>A post-hoc extrapolation exercise based on clinical studies MenACWY-TT-087 and MenACWY-TT-083 was carried out by the MAH. The data presented support (i) a 2+1 posology for infants aged 6 weeks to 6 months and (ii) a 1+1 posology for infants from 6 to 12 months of age.</p> <p>The posology instructions in SmPC section 4.2 have been re-written in line with the accepted posology and presented under new headings to emphasise 'Primary immunisation' vs 'Booster doses'. Within each heading, the instructions have been stratified by age group.</p> <p>Sections 4.4, 4.8 and 5.1 have also been updated with the appropriate information relating to the updated posology.</p>

					The PL has been updated accordingly.
II/0086/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products</p> <p>B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>	24/01/2019	n/a		
II/0083	Update of section 4.4 of the SmPC in order to include	13/12/2018	04/10/2019	SmPC	Based on the review of the literature reports well as the

	<p>a safety warning regarding the risk for invasive disease caused by Meningococcal polysaccharide serogroups A, C, W-135 and Y in persons with familial complement deficiencies and persons receiving treatments that inhibit terminal complement activation.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>cases from the MAH's safety database the Nimenrix SmPC has been updated to reflect that persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y, even if they develop antibodies following vaccination with Nimenrix.</p>
IA/0088	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	07/12/2018	n/a		
PSUSA/10044 /201804	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	31/10/2018	n/a		PRAC Recommendation - maintenance
IA/0087/G	<p>This was an application for a group of variations.</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	28/09/2018	n/a		

IB/0085	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	17/09/2018	n/a		
II/0082	B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol	13/09/2018	04/10/2019	SmPC	
T/0080	Transfer of Marketing Authorisation	11/07/2018	30/07/2018	SmPC, Labelling and PL	
IA/0079/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	17/07/2018	n/a		
II/0078	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	12/07/2018	n/a		
IB/0077	B.I.c.1.z - Change in immediate packaging of the AS - Other variation	11/04/2018	n/a		
IAIN/0076/G	This was an application for a group of variations.	26/03/2018	n/a		

	<p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>				
II/0074	<p>Update of sections 4.5 of the SmPC to include new information regarding co-administration of Nimenrix with Boostrix and Cervarix in individuals from the age of 9 to 25 years, based on data from Studies MenACWY-TT-098 (116705- Phase 3 study to demonstrate the non-inferiority of Nimenrix co-administered with Boostrix compared to Nimenrix administered alone) and MenACWY-TT-054 (113823-phase 3 study to demonstrate the non-inferiority of Nimenrix co-administered with Cervarix compared to Nimenrix alone). The Package Leaflet is updated accordingly.</p> <p>The MAH took also the opportunity to make editorial revision to section 4.8 of the SmPC.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	15/03/2018	30/07/2018	SmPC and PL	<p>The MAH has updated the Product Information to include new information regarding co-administration of Nimenrix with a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine and the human papillomavirus vaccine [Types 16, 18] in individuals from the age of 9 to 25 years.</p> <p>The SmPC section 4.5 has been updated as follows:</p> <p>[...]</p> <p>In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).</p> <p>[...]</p> <p>One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is</p>

					<p>unknown. There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap.</p> <p>The PL (section 2) has been updated accordingly.</p> <p>Other medicines and Nimenrix</p> <p>[...]</p> <p>In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).</p>
IB/0075	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	12/03/2018	n/a		
II/0073	C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	22/02/2018	30/07/2018	SmPC	
II/0069	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	25/01/2018	n/a		
PSUSA/10044 /201704	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine	26/10/2017	n/a		PRAC Recommendation - maintenance

	(conjugated to tetanus toxoid carrier protein)				
IA/0072/G	<p>This was an application for a group of variations.</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p>	19/10/2017	n/a		
IB/0070/G	This was an application for a group of variations.	19/10/2017	n/a		

	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation				
IB/0067	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	07/09/2017	n/a		
N/0068	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/08/2017	30/07/2018	Labelling	
IB/0065	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	28/06/2017	n/a		
PSUSA/10044 /201610	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	05/05/2017	n/a		PRAC Recommendation - maintenance
IA/0064	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	26/04/2017	n/a		
R/0059	Renewal of the marketing authorisation.	15/12/2016	16/02/2017	SmPC and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Nimenrix in the approved indication remains favourable and

					therefore recommended the renewal of the marketing authorisation with unlimited validity.
II/0062	B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol	09/02/2017	n/a		
II/0049	Extension of Indication to include a wider paediatric population starting from 6 weeks of age for Nimenrix; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and the RMP (version 6.0) are updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	10/11/2016	12/12/2016	SmPC and PL	Please refer to the published Assessment Report Nimenrix H-2226-II-49-AR.
PSUSA/10044 /201604	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	27/10/2016	n/a		PRAC Recommendation - maintenance
IAIN/0061/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release -	22/09/2016	n/a		

	Not including batch control/testing				
II/0058	<p>Update of section 4.5 of the SmPC in order to add new co-administration compatibility information with Prevenar. Section 5.1 is proposed to be updated following results of a new post hoc analyses conducted to exclude 5 additional subjects from the ATP cohort.</p> <p>In addition, the Marketing authorisation holder (MAH) took the opportunity to align the pharmaceutical form of Nimenrix in Section 3 with its product release specification following a complaint. The Package Leaflet is updated accordingly.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	15/09/2016	12/12/2016	SmPC and PL	
IA/0060	B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits	14/09/2016	n/a		
II/0053	<p>Update of sections 4.2, 4.8 and 5.1 of the SmPC to reflect new booster and persistence data with a follow-up of up to 5 years after vaccination with MenACWY-TT. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC, Labelling and Package Leaflet. An updated RMP version 7.1 was agreed during the procedure.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance</p>	21/07/2016	22/08/2016	SmPC, Labelling and PL	<p>Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines. In clinical trials, the use of Nimenrix as a booster following primary vaccination with Nimenrix or other meningococcal vaccines (quadrivalent meningococcal A, C, W, and Y-DT conjugate vaccine or monovalent MenC conjugate vaccines) was evaluated.</p> <p>Nimenrix booster vaccination after priming in toddlers, children, adolescents and adults: For subjects primed with</p>

	data				<p>Nimenrix aged 1 year and above and boosted with Nimenrix 4 or 5 years later, more than 99.0% of all subjects achieved post-booster SBA titres \geq 1:8 for both assays (studies MenACWY-TT-062, 048, 059, 088). One month after the booster vaccination, the GMTs elicited were significantly higher than those elicited by age matched naïve control groups, indicating that Nimenrix induces immune memory to groups A, C, W-135, and Y. The observed MenC booster response with Nimenrix was similar to that observed in subjects primed and boosted with a monovalent MenC-CRM conjugate vaccine. One year after Nimenrix booster, SBA titres \geq 1:8 persisted in at least 95.5% of subjects (study MenACWY-TT-048, 12 to 23 months of age at primary vaccination).</p> <p>When Nimenrix was used as a booster following primary vaccination with a MenACWY-DT conjugate vaccine or a monovalent MenC conjugate vaccine (study MenACWY-TT-059, 10 to 25 years of age at primary vaccination and study MenACWY-TT-088, 2 to 10 years of age at primary vaccination), the titres increased by 48-340 fold for all groups and 100% of the subjects reached SBA titres \geq 1:8. The local and general adverse reaction profile of a booster dose of Nimenrix after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except gastrointestinal symptoms (including diarrhoea, vomiting, and nausea) which were very common.</p>
II/0045	Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to amend the information related to	23/06/2016	29/07/2016	SmPC, Annex II, Labelling	Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to amend the information related to the

	<p>the vaccination phase of study MenACWY-TT-104 which includes immunogenicity results for the meningococcal vaccine antigens, and reactogenicity and safety up to one month after vaccination with one or two MenACWY-TT doses in toddlers. This change amends the condition related to study MenACWY-TT-104. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet.</p> <p>In addition the MAH is updating Annex II and IIIA in accordance with the QRD template (v.9.1).</p> <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>			and PL	<p>vaccination phase of study MenACWY-TT-104 which includes immunogenicity results for the meningococcal vaccine antigens, and reactogenicity and safety up to one month after vaccination with one or two MenACWY-TT doses in toddlers. This variation amends the condition related to study MenACWY-TT-104.</p>
IB/0056/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New</p>	24/06/2016	n/a		

	<p>storage site of MCB and/or WCB</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB</p> <p>B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB</p>				
IB/0055/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p>	31/05/2016	n/a		

of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
B.I.b.1.z - Change in the specification parameters				

PSUSA/10044 /201510	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	13/05/2016	n/a		PRAC Recommendation - maintenance
IB/0054	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	21/04/2016	n/a		
IAIN/0052	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	15/01/2016	29/07/2016	Annex II and PL	
IAIN/0051	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	12/01/2016	n/a		
IB/0048/G	This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	17/12/2015	n/a		

T/0047	Transfer of Marketing Authorisation	13/11/2015	16/12/2015	SmPC, Labelling and PL	
IA/0046	B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	12/11/2015	n/a		
PSUSA/10044 /201504	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	06/11/2015	n/a		PRAC Recommendation - maintenance
IB/0044/G	This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	18/09/2015	n/a		
WS/0748	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.z - Change in test procedure for AS or	30/07/2015	n/a		

	starting material/reagent/intermediate - Other variation				
IB/0043/G	<p>This was an application for a group of variations.</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p>	15/07/2015	n/a		
PSUSA/10044 /201410	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)	07/05/2015	n/a		PRAC Recommendation - maintenance
II/0040	Update of section 5.1 of the SmPC based on the results of a re-analysis that was performed excluding immunogenicity data from subjects impacted by GCP deviations for studies MenACWY-TT-036, MenACWY-	26/03/2015	28/07/2015	SmPC	The information in section 5.1 of the SmPC for 3 of the original Nimenrix studies has been updated as a consequence of the reanalysis of data following issues identified with GCP. The MAH has excluded data from

	<p>TT-043 and MenACWY-TT-038, and which included antibody persistence Year 3- and Year 4- results from study MenACWY-TT-043, and Year 4- results for study MenACWY-TT-032. Further, the pooling of clinical safety data in section 4.8 of the SmPC has been updated, and section 4.2 of the SmPC has been updated with removal of the sentence on the need for a booster dose for increased clarity.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>subjects who had not been properly consented, or where serological data was missing. This includes 119 subjects from MenACWY-TT-036 (out of a total of 1025 subjects), 106 subjects from MenACWY-TT-038 (out of a total of 1501 subjects), and 9 subjects from MenACWY-TT-043 (out of a total of 689 subjects). The reason for the majority of exclusions from MenACWY-TT-036 and MenACWY-TT-038 was consent issues, rather than missing serological data. Furthermore, data from Years 3 and 4 in study MenACWY-TT-036 show persistent immunogenicity in adolescents. Persistence results from study MenACWY-TT-032 (Years 4 and 5 in toddlers) have also been updated to try to minimise the potential of selection bias, since subjects with rSBA MenC titres <8 before Year 4 were offered revaccination and excluded from later time points. The MAH has therefore updated the Year 4 immunogenicity data to reflect the cohort for whom Year 5 data are presented. It is agreed that this presentation of the immunogenicity data is more meaningful, and more accurately describes the persistence of response through Years 4 and 5. The MAH has also presented updated pooled safety information including data from two additional studies. An update without data from excluded sites following issues identified with GCP has also been presented. These updates do not significantly affect the reporting rates of solicited or unsolicited symptoms in either age-group. The variation does not have any impact on the overall benefit risk balance of Nimenrix, which remains positive.</p>
II/0038	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of	26/03/2015	28/07/2015	Annex II	

	change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
II/0036	B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP	26/03/2015	n/a		
II/0037	To widen the approved specification limit of the description test performed during quality control release testing and stability testing of Nimenrix conjugate bulks. B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP	26/02/2015	n/a		
WS/0663	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	26/02/2015	n/a		

II/0033	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes	18/12/2014	n/a		
IG/0498	B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised	21/11/2014	n/a		
WS/0600	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change in test procedure for the finished product B.II.d.2.z - Change in test procedure for the finished product - Other variation	20/11/2014	n/a		
WS/0615	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. minor change in the manufacturing process of the active substance B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	20/11/2014	n/a		

PSUV/0027	Periodic Safety Update	06/11/2014	n/a		PRAC Recommendation - maintenance
IG/0468	B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	20/08/2014	n/a		
IB/0028	B.II.f.1.a.3 - Stability of FP - Reduction of the shelf life of the finished product - After dilution or reconstitution	20/08/2014	28/07/2015	SmPC, Labelling and PL	
IB/0029/G	This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	12/08/2014	n/a		

	authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation				
IB/0025	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	08/08/2014	n/a		
PSUV/0020	Periodic Safety Update	22/05/2014	18/07/2014	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0020.
IG/0446	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	24/06/2014	n/a		
IB/0024	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	13/06/2014	n/a		
WS/0493	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	25/04/2014	n/a		
IA/0022	A.7 - Administrative change - Deletion of manufacturing sites	18/04/2014	n/a		

II/0009	<p>Update of SmPC section 5.1 with long term data (up to 4 years after primary vaccination) on antibody persistence and booster response. The statements of persistence of serum bactericidal antibody titres in SmPC section 4.4 has been updated accordingly. In addition, editorial changes have been made in SmPC sections 4.2 and 5.1 and the Annex II has been updated in line with latest QRD template version.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>	20/02/2014	23/04/2014	SmPC and Annex II	Please refer to the assessment report: Nimenrix-H-C-2226-II-09-AR
II/0016	<p>Submission of results of a 5 year follow-up study of the pivotal phase III study MenACWY-TT-039. The study report was submitted in line with requirements of Article 46 of Regulation (EC) No 1901/2006. The requested variation proposed no amendments to the PI.</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>	23/01/2014	n/a		Please refer to the assessment report: Nimenrix-H-C-2226-II-16-AR
IAIN/0019/G	<p>This was an application for a group of variations.</p> <p>C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring</p> <p>A.z - Administrative change - Other variation</p>	18/12/2013	n/a		

IB/0018	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	17/12/2013	n/a		
IB/0017	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	02/12/2013	n/a		
IA/0015	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	25/10/2013	n/a		
II/0014	Update of SmPC sections 5.1 and 4.8 with immunogenicity and safety data in individuals above 55 years of age, based on results of a phase IIIb, open label, randomised, controlled study. In SmPC section 4.2 the statement on absence of data in elderly population is being removed accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	24/10/2013	23/04/2014	SmPC	The MAH submitted results of a study, where single dose of Nimenrix was administered to 194 Lebanese adults 56 years of age and older (including 133 aged 56-65 years and 61 aged > 65 years). The percentage of subjects with rSBA titres (measured at MAH's laboratories) \geq 128 before vaccination ranged from 45% (MenC) to 62% (MenY). Overall, at one month post-vaccination the percentage of vaccinees with rSBA titres \geq 128 ranged from 93% (MenC) to 97% (MenY). In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres \geq 128 at one month post-vaccination ranged from 90% (MenA) to 97% (MenY). All adverse reactions reported in this study were already observed in younger age groups.
WS/0381	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a	24/10/2013	n/a		

	manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product				
WS/0383	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Changes on the manufacturing process of the active substance.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol</p>	27/06/2013	n/a		
IG/0306	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	12/06/2013	n/a		
IG/0304	A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	17/05/2013	23/04/2014	Annex II	
IG/0297	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/04/2013	n/a		
II/0005	<p>Change in the manufacturing process of the finished product.</p> <p>B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a</p>	21/03/2013	n/a		

	manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product				
IA/0007	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	04/02/2013	n/a		
IG/0265/G	This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	28/01/2013	n/a		
WS/0340	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change of specifications of reagent. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	17/01/2013	n/a		

IB/0003/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place</p> <p>B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation</p>	05/10/2012	n/a		
IAIN/0001	<p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p>	17/07/2012	n/a		
IAIN/0002/G	<p>This was an application for a group of variations.</p> <p>C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV</p> <p>C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system</p>	12/07/2012	n/a		